The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: In multiple sclerosis, development of screening tools for remyelination-promoting molecules is timely. Objective: A Xenopus transgenic line allowing conditional ablation of myelinating oligodendrocytes has been adapted for in vivo screening of remyelination-favoring molecules. Methods: In this transgenic, the green fluorescent protein reporter is fused to E. coli nitroreductase and expressed specifically in myelinating oligodendrocytes. Nitroreductase converts the innocuous pro-drug metronidazole to a cytotoxin. Spontaneous remyelination occurs after metronidazole-induced demyelinating responses. As tadpoles are transparent, these events can be monitored in vivo and quantified. At the end of metronidazole-induced demyelination, tadpoles were screened in water containing the compounds tested. After 72 h, remyelination was assayed by counting numbers of oligodendrocytes per optic nerve. Results: Among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination. Crispr/cas9 gene editing showed that the promyelinating effect of siponimod involves the sphingosine-1-phosphate receptor 5. Conclusion: This Xenopus transgenic line constitutes a simple in vivo screening platform for myelin repair therapeutics. We validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991
Rejuvenation of Regeneration in the Aging Central Nervous System
Ruckh, J. M., Zhao, J.-W., Shadrach, J. L., van Wijngaarden, P., Rao, T. N., Wagers, A. J., & Franklin, R. J. M. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2011.11.019 · Cited by 649
Retinoid X receptor gamma signaling accelerates CNS remyelination
Huang, J. K., Jarjour, A. A., Nait Oumesmar, B., Kerninon, C., Williams, A., Krezel, W., Kagechika, H., Bauer, J., Zhao, C., Evercooren, A. B.-V., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2702 · Cited by 547
Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo
Najm, F. J., Madhavan, M., Zaremba, A., Shick, E., Karl, R. T., Factor, D. C., Miller, T. E., Nevin, Z. S., Kantor, C., Sargent, A., et al. (2015) · Nature · doi:10.1038/nature14335 · Cited by 424
Tyler, W. A., Gangoli, N., Gokina, P., Kim, H. A., Covey, M., Levison, S. W., & Wood, T. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0234-09.2009 · Cited by 263
Cited by
Remyelination in multiple sclerosis: From basic science to clinical translation
Lubetzki, C., Zalc, B., Williams, A., Stadelmann, C., & Stankoff, B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30140-x · Cited by 350
Self-citationThe role of glial cells in multiple sclerosis disease progression
Healy, L. M., Stratton, J. A., Kuhlmann, T., & Antel, J. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00624-x · Cited by 152
Remyelination in Multiple Sclerosis: Findings in the Cuprizone Model
Leo, H., & Kipp, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416093 · Cited by 46
Metadata
- Authors
- Mannioui, A., Vauzanges, Q., Fini, J. B., Henriet, E., Sekizar, S., Azoyan, L., Thomas, J. L., Pasquier, D. D., Giovannangeli, C., Demeneix, B., Lubetzki, C., & Zalc, B.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2017-07-28
- Volume
- 24
- Issue
- 11
- Pages
- 1421-1432
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2740199658
- Cited by
- 71
- References
- 5
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination. https://app.cochat.ai/papers/10.1177/1352458517721355
- The paper
- Mannioui, A., Vauzanges, Q., Fini, J. B., Henriet, E., Sekizar, S., Azoyan, L., Thomas, J. L., Pasquier, D. D., Giovannangeli, C., Demeneix, B., Lubetzki, C., & Zalc, B. (2018). The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458517721355
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.